TY - JOUR T1 - Liquid-biopsy transcriptomic profiling uncovers molecular mediators of resistance to androgen receptor signaling inhibition in lethal prostate cancer JF - medRxiv DO - 10.1101/2021.11.01.21265757 SP - 2021.11.01.21265757 AU - Jiaren Zhang AU - Bob Zimmermann AU - Giuseppe Galletti AU - Susan Halabi AU - Ada Gjyrezi AU - Qian Yang AU - Santosh Gupta AU - Akanksha Verma AU - Andrea Sboner AU - Monika Anand AU - Daniel J. George AU - Simon G. Gregory AU - Seunghee Hong AU - Virginia Pascual AU - Clio P. Mavragani AU - Emmanuel S. Antonarakis AU - David M. Nanus AU - Scott T. Tagawa AU - Olivier Elemento AU - Andrew J. Armstrong AU - Paraskevi Giannakakou Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/02/2021.11.01.21265757.abstract N2 - Androgen receptor signaling inhibitors (ARSi) are a mainstay for patients with metastatic castration-resistant prostate cancer (mCRPC). However, patient response is heterogeneous and the molecular underpinnings of ARSi resistance are not well elucidated. Here we performed transcriptome analysis of circulating tumor cells (CTCs) and peripheral blood mononuclear cells (PBMC) in the context of a prospective clinical trial of men with mCRPC treated with abiraterone (Abi) or enzalutamide (Enza). CTC RNA-sequencing identified that RB loss and enhanced E2F signaling along with BRCA loss transcriptional networks were associated with intrinsic ARSi resistance, while an inflammatory response signature was significantly associated with acquired resistance. Transcriptomic analysis of matching PBMCs identified enrichment of inflammasome gene signatures indicative of activated innate immunity at progression, with concurrent downregulation of T and NK cells. Importantly, CTC gene signatures had a significant positive association with circulating immune macroenvironment (CIME) signatures. Taken together, these data demonstrate that liquid biopsy transcriptomics can identify molecular pathways associated with clinical ARSi resistance paving the way for treatment optimization in patients with mCRPC.Competing Interest StatementDr. Antonarakis reports grants and personal fees from Janssen, personal fees from Astellas, grants and personal fees from Sanofi, grants and personal fees from Dendreon, personal fees from Pfizer, personal fees from Invitae, grants and personal fees from AstraZeneca, grants and personal fees from Clovis, grants and personal fees from Merck, grants from Johnson&Johnson, grants from Genentech, grants from Novartis, grants from Bristol Myers-Squibb; and also has a patent (PCT/US2015/046806) on an AR-V7 biomarker technology licensed to Qiagen. Dr. Armstrong: research funding to Duke from Pfizer, Genentech/Roche, Astellas, Janssen, Dendreon, Bayer, Constellation, AstraZeneca, Merck, BMS, Amgen, Celgene, Beigene, Forma, Amgen. Consulting with Pfizer, Astellas, Janssen, Dendreon, Bayer, AstraZeneca, Merck, BMS, Amgen, Celgene, Clovis, Forma.Clinical TrialNCT02269982Funding StatementProstate Cancer Foundation; Department of Defense; NIH;Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients provided written informed consent in accordance with Declaration of Helsinki ethical guidelines; Institutional Review Board (IRB) approval was obtained from Duke University IRB or Weill Cornell Medicine IRBI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -